Rapport Therapeutics, Inc. (NASDAQ: RAPP) announced a licensing agreement with Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. for RAP-219, a first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator in development for focal onset seizures (FOS) and the manic phase of bipolar disorder. The deal grants Tenacia Bio exclusive Greater China rights and provides Rapport with $20 million upfront plus up to $308 million in milestones and tiered royalties up to high teens.
Regulatory advantage – domestic developer status for NMPA priority review
Market Context & Commercial Outlook
Factor
Implication
China Epilepsy Market
~9 million patients; RMB 15+ billion annually; high unmet need for focal seizure control with improved tolerability
Bipolar Disorder in China
~8 million diagnosed; limited approved therapies for acute mania; significant hospitalization burden
TARPγ8 Mechanism Advantage
CNS-selective modulation may offer cognitive-sparing profile vs. non-selective AMPA modulators; addresses unmet tolerability need
First-in-Class Premium
Novel mechanism supports premium pricing and formulary preference in China innovative drug catalog
Revenue Potential
Peak China sales RMB 800 million–1.2 billion (FOS + bipolar); Tenacia break-even on milestones by 2032
Development Timeline: Tenacia to initiate China Phase I/II 2027; parallel Rapport U.S. pivotal studies support potential simultaneous global filings 2030
Deal Structure Comparison: $328M total consideration aligns with recent China CNS licensing benchmarks (e.g., Karuna/Xenocraft, Cerevel/BeiGene)
Forward‑Looking Statements This brief contains forward‑looking statements regarding milestone achievement, clinical development progress, and commercial potential for RAP-219 in Greater China. Actual results may differ due to CNS drug development risks, regulatory requirements for novel mechanisms, and competitive dynamics in the epilepsy and bipolar disorder markets.-Fineline Info & Tech
By Fineline Cube